Company profile: Theranexus
1.1 - Company Overview
Company description
- Provider of clinical-stage therapies for brain disorders, including Batten-1, a drug candidate targeting Batten disease by blocking glycosphingolipid accumulation and neuro-inflammation to prevent brain cell death, and NeuroLead, a discovery platform for innovative therapy candidates in rare neurological disorders developed with CEA and Collège de France.
Products and services
- NeuroLead platform: Collaboration-developed discovery platform that identifies innovative therapy candidates for rare neurological disorders, leveraging CEA and Collège de France expertise and methodologies
- Batten-1: A clinical-stage drug candidate engineered to target Batten disease by blocking glycosphingolipid accumulation and neuro-inflammation, aiming to prevent brain cell death.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Theranexus
Sooma Medical
HQ: Finland
Website
- Description: Provider of non-invasive tDCS-based brain stimulation therapies and devices for depression and chronic pain. Offers Sooma Duo, integrating a tDCS device with a digital platform for remote patient guidance and clinical management; Sooma Depression Therapy for MDD; Sooma Pain Therapy for fibromyalgia and chronic neuropathic pain; and a portable tDCS device with accessories and an online platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sooma Medical company profile →
Vigil Neuroscience
HQ: United States
Website
- Description: Provider of therapeutics and programs for neurodegenerative diseases, including iluzanebart (a fully human monoclonal antibody targeting TREM2) for ALSP, an oral small molecule TREM2 agonist program for common diseases like Alzheimer's, the ILLUMINATE natural history study and IGNITE Phase 2 trial in ALSP, and the ALSPAware no-cost genetic testing and counseling program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vigil Neuroscience company profile →
Advantage Therapeutics
HQ: United States
Website
- Description: Provider of therapies for neurodegenerative conditions focused on Alzheimer’s Disease, including AD04, a novel immunotherapy for mild Alzheimer’s utilizing a proprietary approach to stimulate and regulate the immune system; klotho protein research into aging and neurodegenerative diseases; and a Phase 2b randomized, double-blind, placebo-controlled trial of AD04 across multiple European countries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advantage Therapeutics company profile →
Jazz Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceuticals for underserved neurology and psychiatry markets. Includes Xyrem and Xywav for cataplexy and excessive daytime sleepiness in narcolepsy; Epidiolex for seizures in Lennox-Gastaut syndrome, Dravet syndrome, or Tuberous Sclerosis Complex; Vyxeos for acute myeloid leukemia; Zepzelca for metastatic small cell lung cancer; Defitelio for hepatic veno-occlusive disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jazz Pharmaceuticals company profile →
Trophos
HQ: France
Website
- Description: Provider of clinical-stage pharmaceutical R&D developing innovative therapeutics for under-served needs in neurology and cardiology, with a pipeline of original molecules targeting motoneuron diseases such as amyotrophic lateral sclerosis (ALS).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trophos company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Theranexus
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Theranexus
2.2 - Growth funds investing in similar companies to Theranexus
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Theranexus
4.2 - Public trading comparable groups for Theranexus
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →